TCR² Therapeutics to Present at J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Dec. 21, 2020 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that Garry Menzel, Ph.D., President and Chief Executive Officer of TCR2 Therapeutics, will present an update on Company progress at the 39th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, 2021 at 7:30am E.T. using a virtual platform.

A live webcast of the presentation will be available on the Investors page of the Company’s website at www.investors.tcr2.com. An archived replay will be available for at least 30 days following the presentation.

About TCR2 Therapeutics

TCR2 Therapeutics Inc. is a clinical-stage immunotherapy company developing a pipeline of novel T cell therapies for patients suffering from solid tumors or hematological malignancies. TCR2’s proprietary T cell receptor (TCR) Fusion Construct T cells (TRuC®-T cells) specifically recognize and kill cancer cells by harnessing signaling from the entire TCR, independent of human leukocyte antigens (HLA). In preclinical studies, TRuC-T cells have demonstrated superior anti-tumor activity compared to chimeric antigen receptor T cells (CAR-T cells), while secreting lower levels of cytokine release. The Company’s lead TRuC-T cell product candidate targeting solid tumors, TC-210, is currently being studied in a Phase 1/2 clinical trial to treat patients with mesothelin-positive non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. The Company’s lead TRuC-T cell product candidate targeting hematological malignancies, TC-110, is currently being studied in a Phase 1/2 clinical trial to treat patients with CD19-positive adult acute lymphoblastic leukemia (aALL) and with aggressive or indolent non-Hodgkin lymphoma (NHL). For more information about TCR2, please visit www.tcr2.com.

Investor and Media Contact:

Carl MauchDirector, Investor Relations and Corporate CommunicationsTCR2 Therapeutics Inc.(617) 949-5667[email protected]

You May Also Be Interested In

• Rocket Lab Satellite Platforms Built for MDA Space Successfully Reach Orbit, Supporting Globalstar Direct-to-Device Communications Services
• Crypto News Today: MemeToro Presale Gains Attention as JPMorgan Boosts IBIT and ETHA Holdings by Double Digits
• 3 Top Crypto to Buy Now While Fear Takes Over and One Presale Keeps Pulling in Millions